发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Patent highlights December 2022-January 2023. 专利亮点2022年12月至2023年1月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-10-06 DOI: 10.4155/ppa-2023-0016
Hermann Am Mucke
{"title":"Patent highlights December 2022-January 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0016","DOIUrl":"10.4155/ppa-2023-0016","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41149760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications. 关于三维打印技术在制药和生物医学应用中的作用的最新专利综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.4155/ppa-2023-0018
Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav
{"title":"Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications.","authors":"Palak Rani, Vikas Yadav, Parijat Pandey, Kiran Yadav","doi":"10.4155/ppa-2023-0018","DOIUrl":"10.4155/ppa-2023-0018","url":null,"abstract":"<p><p>Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug. In the present review, we have highlighted the potential benefits of 3DP technology in healthcare, such as the ability to create patient-specific medical devices and implants, as well as the possibility of on-demand production of drugs and personalized dosage forms. We have further discussed future research to optimize 3DP processes and materials for pharmaceutical and biomedical applications. Cohesively, we have put forward the current state of active patents and applications related to 3DP technology in the healthcare and pharmaceutical industries including hearing aids, prostheses, medical devices and drug-delivery systems.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review. 咪唑 [2,1-b] [1,3,4]- 噻二唑类似物的治疗魅力：专利回顾。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0006
Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal
{"title":"Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review.","authors":"Anuradha Mehra, Rekha Sangwan, Aryan Mehra, Shivani Sharma, Pankaj Wadhwa, Amit Mittal","doi":"10.4155/ppa-2023-0006","DOIUrl":"10.4155/ppa-2023-0006","url":null,"abstract":"<p><p>Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015-2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent landscape of platelet growth factor receptor and c-KIT targets. 血小板生长因子受体和c-KIT靶点的专利前景。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-09-27 DOI: 10.4155/ppa-2023-0005
Hai-Long Zhang, Qian Kong
{"title":"Patent landscape of platelet growth factor receptor and c-KIT targets.","authors":"Hai-Long Zhang, Qian Kong","doi":"10.4155/ppa-2023-0005","DOIUrl":"10.4155/ppa-2023-0005","url":null,"abstract":"<p><p>Type III receptor tyrosine kinase, e.g., PDGFR, are associated with various autoimmune diseases. To show the status of PDGFR and c-KIT targets, we performed the US patent analysis. The present study showed that the R&D of c-KIT target was much earlier than the R&D of PDGFR targets. Currently, the PDGFR-based target demonstrates more applications in the development of biological therapy. Our findings indicated that some inhibitors of c-KIT target contained sulfur elements or 1,3-diazine rings. The c-KIT target has more competitive edges for chemical drug discovery than the PDGFR target. c-KIT and PDGFR targets are currently preferable for drug discovery in autoimmune diseases. This study was the first to show R&D differentiation between PDGFR and c-KIT targets in drug development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41139705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug repurposing of mito-atovaquone for cancer treatment. Mito-Atovaquone用于癌症治疗的药物再利用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-07-01 Epub Date: 2023-10-06 DOI: 10.4155/ppa-2023-0015
Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Martin Perez-Santos
{"title":"Drug repurposing of mito-atovaquone for cancer treatment.","authors":"Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Martin Perez-Santos","doi":"10.4155/ppa-2023-0015","DOIUrl":"10.4155/ppa-2023-0015","url":null,"abstract":"<p><p>Repurposing of approved drugs in a new strategy to combat cancer that leads to savings in time and investment. Atovaquone is a US FDA-approved drug for treatment of <i>Pneumocystis carinii</i> pneumonia and malaria. Patent US2023017373 describe the use of mito-atovaquone for the treatment of several types of cancer. Mito-atovaquone demonstrated antiproliferative activity in cell lines of pancreatic cancer, lung cancer and brain cancer and inhibited tumor growth in syngeneic mouse models and in animals genetically prone to breast cancer. Mito-atovaquone has the potential to be used successfully in the treatment of various types of tumors.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent profile for the approved and in clinical trials Mpox vaccines. 已批准和正在进行临床试验的猴痘疫苗的专利简介。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0017
Irene von der Weid, Cristina d'Urso de Souza Mendes, Paula C Fonseca, Sandro G Viveiros Rosa
{"title":"Patent profile for the approved and in clinical trials Mpox vaccines.","authors":"Irene von der Weid, Cristina d'Urso de Souza Mendes, Paula C Fonseca, Sandro G Viveiros Rosa","doi":"10.4155/ppa-2023-0017","DOIUrl":"10.4155/ppa-2023-0017","url":null,"abstract":"<p><p>Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights October-November 2022. 专利亮点2022年10月至11月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-05-01 Epub Date: 2023-07-21 DOI: 10.4155/ppa-2023-0008
Hermann Am Mucke
{"title":"Patent highlights October-November 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0008","DOIUrl":"10.4155/ppa-2023-0008","url":null,"abstract":"<p><p>A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morita-Baylis-Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities. Morita-Baylis-Hillman加合物及其衍生物：对多种生物活性的专利探索。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0021
Ricardo S Porto, Viviane A Porto
{"title":"Morita-Baylis-Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities.","authors":"Ricardo S Porto,&nbsp;Viviane A Porto","doi":"10.4155/ppa-2023-0021","DOIUrl":"10.4155/ppa-2023-0021","url":null,"abstract":"<p><p>Morita-Baylis-Hillman adducts are polyfunctionalized compounds that result from a three-component reaction involving an electrophilic sp<sup>2</sup> carbon (aldehyde, ketone or imine) and the α-position of an activated alkene, catalyzed by a tertiary amine. These adducts exhibit a wide range of biological activities and act as valuable starting materials for developing drug candidates, pesticides, polymers, and other applications. In this regard, the present review aimed to explore the biological potential of Morita-Baylis-Hillman adducts and their derivatives as documented in patent literature. Additionally, the review delves into the synthetic methodologies employed in their preparation.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023. 治疗阿尔茨海默病的新型治疗方法专利分析2018-2023。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-05-01 Epub Date: 2023-07-21 DOI: 10.4155/ppa-2023-0020
Faiza Saleem, Fouzia Naz, Khalid M Khan
{"title":"Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023.","authors":"Faiza Saleem,&nbsp;Fouzia Naz,&nbsp;Khalid M Khan","doi":"10.4155/ppa-2023-0020","DOIUrl":"10.4155/ppa-2023-0020","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current landscape and future prospects of RET and ROS1 targets. RET和ROS1目标的现状和未来前景。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-05-01 Epub Date: 2023-09-06 DOI: 10.4155/ppa-2023-0011
Hai-Long Zhang, Qian Kong
{"title":"Current landscape and future prospects of RET and ROS1 targets.","authors":"Hai-Long Zhang,&nbsp;Qian Kong","doi":"10.4155/ppa-2023-0011","DOIUrl":"10.4155/ppa-2023-0011","url":null,"abstract":"<p><p>RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique elements compared with inhibitor structures of RET or BRAF targets. Our study was the first time to uncover that a number of inhibitor structures of ROS1 target contained sulfur and boron elements. The inhibitors of RET target could be developed for treatment of various cancers, including lung cancer, thyroid cancer, and other solid tumor, while the inhibitors of ROS1 target are virtually developed for treatment of lung cancer. Our findings provide a new insight for drug discovery of ROS1 and RET target.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10163336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信